ADOCIA CORPORATE PRESENTATION
|
|
- Joy Elliott
- 8 years ago
- Views:
Transcription
1 ADOCIA CORPORATE PRESENTATION
2 Disclaimer This document has been prepared by Adocia (the "Company") and is provided for information purposes only. The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice. The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein. This document contains information on the Company s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company s own estimates. Investors should not base their investment decision on this information. This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company s financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document. This document does not constitute an offer to sell or subscribe or a solicitation to purchase or subscribe for securities in France, the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration thereunder. No public offering of securities will be conducted in France or abroad prior to the delivery by the French Autorité des marchés financiers (Financial Markets Authority) of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE as amended. No public offering of securities is contemplated in France or any jurisdiction outside France. The distribution of this document may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. September 2014 Property of Adocia 2
3 Adocia - Management Gérard Soula Olivier Soula Valérie Danaguezian Rémi Soula President & CEO Deputy General Manager Chief Financial Officer Business Development R&D Director & Intellectual Property Director Property of Adocia 3
4 Adocia in brief Founded end of 2005 by Gérard, Olivier and Rémi Soula Listed on Euronext Paris since February 2012 Experienced management and collaborators, including 24 Ph.Ds Cash position close to 16 M at end of June 2014 Platform technologies BioChaperone platform: a major leap to improve protein performance (insulin, growth factors, mabs ) DriveIn platform: nanotechnology for targeted drug delivery in oncology New technologies for mab formulation 3 therapeutic areas Diabetes: Unique portfolio of 3 insulin products in clinical development Wound healing, Diabetic Foot Ulcer treatment: BioChaperone PDGF Oncology: DriveIn-Doxorubicin and DriveIn-Docetaxel, for the treatment of solid tumors September 2014 Property of Adocia 4
5 2014, an exceptional starting-up. Three major clinical results Ultra-fast BC Lispro tested on 36 Type 1 diabetic patients Higher performance compared to Humalog by 40% Interest from various companies on this product patented up to 2033 Ultra-fast BC Lispro tested at three different doses Proportional dose-exposure showed Confirmation of previous results BC Combo based with glargine and lispro tested on 20 Type 1 diabetic patients Higher performance compared to HumalogMix Interest from two companies for this unique product patented up to 2032 Three new clinical studies Biochaperone PDGF-BB, phase III clinical trial on 252 patients: launched! HinsBet, optimized formulation on 36 Type 1 diabetics: ongoing New clinical dose-response study on the BC glargine formulation: on preparation Increased visibility of Adocia Launch of ADR (American Deposit Receipt) program mnemonic: ADOCY Clinical results presented at American Diabete Association (ADA) and at European Association for the Study of Diabetes (EASD) September 2014 Property of Adocia 5
6 Evolution of the stock over the first months of 2014 Phase II combo Results Phase IIa UF Lispro Results Start of Phase II effet-dose UF Lispro Lispro 300U Project Start of Phase IIa Hinsbet Start of Phase III BC PDGF-BB IPO : 15,88 DFU Patent ADR Start of Phase IIa UF Lispro ADA posters Increase of the shareprice ( 5.97 on 1st January on 2 nd September), associated with an increase of the average exchanged volume (6.200 in 2013 and in 2014) September 2014 Property of Adocia 6
7 Adocia: a solid and diversified portfolio of products September 2014 Property of Adocia 7
8 Products breakthrough 1. Insulin therapy 2. Wound healing 3. Oncology September 2014 Property of Adocia 8
9 Diabetes: a significant and growing pandemic 95 M Treated 206 M Diagnosed 382 M Diabetics +55% 592 M Diabetics September 2014 Property of Adocia 9 Adapted from International Diabetes Federation, Diabetes Atlas, 6 th Edition, 2013
10 Insulin is the ultimate treatment for T2D patients, and the only option for T1D patients Treatment intensification $23 B Oral Antidiabetics GLP-1 Insulin 25% Treated diabetics use Insulin Disease progression September 2014 Property of Adocia 10
11 Two major types of insulin products 70 Prandial insulins (Humalog, Novolog, Apidra ) Insulin (µu/ml) Basal insulins (Lantus, Levemir, Tresiba ) 10 6:00 10:00 14:00 18:00 22:00 2:00 6:00 Breakfast Lunch Dinner September 2014 Property of Adocia 11 (1) Figures for 2013, based on data from Novo Nordisk, Full year 2013 presentation Feb 2014; Companies Financial reports 4Q13 & Sanofi s Annual Report 2013.
12 Insulin: more than 90 years towards a progress towards a more physiological treatment September 2014 Property of Adocia 12
13 but the insulin landscape is undergoing major changes Humalog BC Combo Glargine/Fast Oncea-week HinsBet September 2014 Property of Adocia 13
14 BioChaperone for Prandial insulins September 2014 Property of Adocia 14
15 Faster insulins enables meal-time dosing. - - September 2014 Property of Adocia 15
16 leading to better diabetes management Ultra-fast insulins Injection adapted to the real meal Improved medical benefit Less hyper-glycemic events Less hypo-glycemic events September 2014 Property of Adocia 16
17 Ultra-fast insulin is a major key for Prandial insulins BC Lispro Children Insulin pumps Artificial pancreas Better Treatment Dosage accuracy, adapted to the meal Improvement of the Regulation but also for all users of prandial insulin September 2014 Property of Adocia 17
18 Results of phase 2a trial on 36 Type 1 Diabetic patients CT006 Pharmacokinetics «faster-in» and «faster-out» Prandial insulins BC Lispro U100 Mean Serum insulin level September 2014 Property of Adocia 18 Double blind study, randomized, cross-over study on 36 Type 1 Diabetic patients under euglycemic clamp; BC Lispro (100 IU) vs. Humalog (100IU)
19 Phase 2a trial on 36 T1D patients Pharmacodynamics Prandial insulins BC Lispro U100 Mean Glucose Infusion Rate September 2014 Property of Adocia 19 Double-blind, randomized, cross-over study on 36 Type 1 Diabetic patients under euglycemic clamp; BC Lispro vs. Humalog 100 IU
20 Compiled results CT006-CT008 BC Lispro [Prelim.] Pharmacokinetics at 0.2 U/kg Prandial insulins BC Lispro U100 Phase 2a dose-response CT patients type 1 BC Lispro Humalog Zoom 0-2h Phase 2a CT patients type 1 BC Lispro Humalog The results of the new clinical trial CT008 confirm a faster absorption of BioChaperone Lispro compared to Humalog. September 2014 Property of Adocia 20
21 Compiled results CT006-CT008 BC Lispro [Prelim.] Pharmacodynamics at 0.2 U/kg Prandial insulins BC Lispro U100 Phase 2a dose-response CT patients type 1 BC Lispro Humalog Zoom 0-2h Phase 2a CT patients type 1 BC Lispro Humalog The faster absorption is confirmed by a pharmacological effect significantly earlier with BC Lispro. September 2014 Property of Adocia 21
22 CT008 BC Lispro results on 37 patients with T1 diabetes [Prelim.] Dose-exposure relationship Prandial insulins BC Lispro U100 BC Lispro 0.4 U/kg BC Lispro 0.2 U/kg BC Lispro 0.1 U/kg For a range of usual prandial insulin doses, BioChaperone Lispro presents an ultra-fast absorption profile. September 2014 Property of Adocia 22
23 CT008 BC Lispro results on 37 patients with T1 diabetes [Prelim.] Dose-exposure relationship Prandial insulins BC Lispro U100 Dose normalization at 0.1 U/kg BC Lispro 0.4 U/kg BC Lispro 0.2 U/kg BC Lispro 0.1 U/kg The dose normalization confirms the dose-exposure proportionality. September 2014 Property of Adocia 23
24 CT008 BC Lispro results on 37 patients with T1 diabetes [Prelim.] Dose-response relationship Prandial insulins BC Lispro U100 BC222 Lispro 0.4 U/kg BC222 Lispro 0.2 U/kg BC222 Lispro 0.1 U/kg Across the range of tested doses, BC Lispro shows an ultra-fast metabolic effect. September 2014 Property of Adocia 24
25 CT008 BC Lispro results on 37 patients with T1 diabetes [Prelim.] Dose-response relationship Prandial insulins BC Lispro U100 Dose normalization at 0.1 U/kg BC222 Lispro 0.1 U/kg BC222 Lispro 0.2 U/kg BC222 Lispro 0.4 U/kg A saturation of the metabolic effect was observed with increasing dose (expected pharmacological effect). A linear increase in early and total metabolic effects was demonstrated in a clinically relevant range of doses ( U/kg). September 2014 Property of Adocia 25
26 Clinical trials with BioChaperone Lispro Conclusions BioChaperone Lispro is an ultra-fast formulation: The absorption and the pharmacological effect are significantly faster than Humalog BioChaperone Lispro presents a clinical robustness performance: The results obtained in the first clinical study are confirmed The formulation presents a proportional dose-exposure relationship, which is shown by a linear dose response across the range of doses usually used by the patients with diabetes. BioChaperone Lispro is well tolerated in humans: No specific serious adverse events have been observed in these 2 trials Local tolerance is excellent with no local reaction at the site injection for the total 149 injections. September 2014 Property of Adocia 26
27 Medical interest of BioChaperone Lispro Conclusions BioChaperone Lispro could have a beneficial effect on all patients using prandial insulins: Flexibility gain on the injection time: Pediatric population Patients with type 1 diabetes Patients with type 2 diabetes Better control of the post-prandial glycaemia: Patients using insulin pens or/and syringes Users of pumps BioChaperone Lispro could lead to new innovations: The ultra-fast PKPD profile is needed for the development of an artificial pancreas September 2014 Property of Adocia 27
28 BC Lispro U100 Next key steps for the clinical development Prandial insulins BC Lispro U100 Glycaemia regulation study, post meal, on patients with type 1 diabetes using insulin pump to prove the medical advantage Clinical trial planned in Q Simplified development plan, following the FIAsp of Novo Nordisk (ultra-fast Novolog) Preparation of meetings pre-ind (FDA) & scientific advice (EMA) to validate the development plan expected 1Q 2015 Phase III clinical trials could be launched starting with 4Q 2015 September 2014 Property of Adocia 28
29 Concentrated, ultra-fast insulin for patients requiring higher doses Prandial insulins BC Lispro U300 Obesity 86% Overweight Type 2 diabetics (2006 study) 1 Severe insulin resistance High insulin doses Need for concentrated ultra fast-acting insulin 1 Daousi et al (2006) Postgrad Med J 2006;82: September 2014 Property of Adocia 29
30 BC Lispro U300 ultra-fast acting Prandial insulins BC Lispro U300 Mean PD results (pig model) 1 st concentrated ultra-fast acting insulin BioChaperone Lispro U300 Humalog U100 Phase I/II planned 1Q 2015 September 2014 Property of Adocia 30
31 Innovation for everyone, everywhere Prandial insulins HinsBet 80% diabetics live in developing countries September 2014 Property of Adocia 31 Source: International Diabetes Federation, Diabetes Atlas, 6 th Edition, 2013
32 Emerging markets: similar needs, different constraints Prandial insulins HinsBet Large populations to treat Strong economic constraints But same medical needs Better glycemic control Prevention of long term complications September 2014 Property of Adocia 32
33 Human insulin is number one in the developing countries Prandial Insulins HinsBet 58% of Novo s insulin sales in China are human insulin Large human insulin manufacturing capabilities in Asia RHI is more cost-effective than analogs RHI is 100% reimbursed in China BUT RHI action starts 15 min later than insulin analogs HinsBet: an human insulin as fast as an insulin analog September 2014 Property of Adocia 33
34 HinsBet, a fast-acting human insulin Prandial insulins HinsBet Mean PD results (pig model) HinsBet NovoLog (aspart) Actrapid (human insulin) Phase 2a dose-response study launched beginning of July 2014 September 2014 Property of Adocia 34
35 BioChaperone for Glargine-based Combo September 2014 Property of Adocia 35
36 Many patients have difficulties with multi-daily insulin injections BC Combo Basal/Bolus Users Semi-compliant patients Obese & poor self-image Not confident or not willing to handle injections Premix Users Non sophisticated patients Elderly Issues with multiple injections Other issues: health literacy, cost Poor compliance & self-management Poor medical performance HbA1c Part of Glargine $8bn Premix $2.4bn September 2014 Property of Adocia 36 Glasgow RE. et al. Diabetes spectrum 2001 ; Skinner TC & Hampson SE Diabetes Care 2001; Gherman A et al. Pract Diab Int 2011
37 Goal: Delivering Glargine & Prandial insulins in a single injection BC Combo Once-a-Day Improved Compliance Fewer injections Easier treatment management Decreased social hindrance HbA1c < 7% Improved HbA1c Faster prandial action Longer basal effect Reconciling patients and physicians about the intensification of insulin therapy September 2014 Property of Adocia 37
38 Results Phase 2a clinical trial in 20 Diabetics Type 1 patients Basal acting >24h, ultra-fast acting prandial BC Combo Mean Glucose Infusion Rate 168 min p= min BioChaperone Combo HumalogMix 25 T onset AUC GIR 0-2h AUC GIR 12-30h -37% (p=0.002) +58% (p=0.001) +57% (p=0.025) September 2014 Property of Adocia 38 Double blind, randomized, cross-over study on 20 Type 1 Diabetics patients under euglycemic clamp; BC Combo (Glargine 300 IU/Lispro 100 IU) vs. HumalogMix
39 BioChaperone Combo: basal acting >24h, Phase 2a clinical trial, 20 Type 1 Diabetics BC Combo Mean blood glucose BioChaperone Combo HumalogMix 25 Number of patients with duration 30h 17/19 for BC Combo vs. 6/20 for Premix (p=0.001) September 2014 Property of Adocia 39 Etude double-aveugle, randomisée, croisée sur 20 diabétiques de type 1 sous clamp euglycémique; BC Combo (Glargine 300 IU/Lispro 100 IU) vs. HumalogMix 25
40 BioChaperone Glargine Lispro Combo has unique advantages BC Combo BioChaperone Glargine advantages vs. Ryzodeg Insulin Glargine long safety and efficacy track-record Potential faster prandial action (based on the results of Phase I/II of the two products) Low cost of production September 2014 Property of Adocia 40
41 Insulins Combo improves medical benefit vs Premix: Ryzodeg (Novo Nordisk) clinical results Improved fasted glucose control Faster achievement of HbA1c target Less insulin consumption Lower rate of hypoglycemia BC Combo is nowadays a direct competitor to Novo s Ryzodeg September 2014 Property of Adocia 41 Source: Novo Nordisk, based on trial NN and NN
42 Next steps for BioChaperone Combo BC Combo Phase IIa dose-response clinical study expected 4Q Type 1 Diabetic patients Dose-exposure relationship measurement Euglycemic clamp Double-blind, randomized, 4-periods crossover Each patient will receive 4 injections of insulin: BC Combo with 3 different doses, and HumalogMix25 with 1 dose Simplified development plan relying on Glargine/Lispro existing results Preparation of meetings pre-ind (FDA) & scientific advice (EMA) to validate the development plan Phase III program could start in 1Q 2016 September 2014 Property of Adocia 42
43 Next developments milestones in BioChaperone insulins Product Event Expected timeline BC Combo HinsBet BioChaperone Lispro U100 BioChaperone Lispro U300 Start Dose-response Phase IIa 4Q 14 Results Dose-response Phase IIa 4Q 14 Start Pump study, post meal Phase IIa 1Q 15 Start Phase I/II on type 1 diabetics 1Q 15 September 2014 Property of Adocia 43
44 BioChaperone Insulin portfolio: Best-in-class products Gold-standard 1 st Generation Best-in-class 2 nd Generation + BioChaperone Established safety and efficacy Daily part of patient lives Simple Short clinical trial Safe and well tolerated Efficacy Medical benefit September 2014 Property of Adocia 44
45 Product Breakthrough 1. Insulin therapy 2. Wound healing 3. Oncology September 2014 Property of Adocia 45
46 Diabetic Foot Ulcer (DFU): a life-threatening disease 10 Million people affected Chronic hyperglycemia Neuropathy & Ischemia Diabetic Foot Ulcer 60 % Neuroischemic patients in Western countries 1 Armstrong, D. G. et al Int Wound J 2007, 4 (4), Property of Adocia 46
47 Wound healing potential market + Severity of disease - S&N ADOCIA Smith&Nephew, DermaSciences Urgo, Convatec, Mölnlycke, Systagenix. Cellular therapies~ $10,000 Biologics~ $1,500 Only approved product for DFU: Regranex (PDGF-BB) Dressings ~$200 Property of Adocia 47
48 Advantages of BioChaperone PDGF-BB vs Regranex Easy to use and convenient Applied once every two days (vs. daily for Regranex) Ready-to-use spray Sterile without preservatives Multi-uses for 6 weeks Stable up to 3 months at 30 C and 30 months at 5 C Cost effective 1/3 of PDGF dosage vs. Regranex Reduced cost of treatment due to reduced frequency BioChaperone PDGF-BB spray meets the requirements for a first-line advanced wound care treatment September 2014 Property of Adocia 48
49 BioChaperone PDGF-BB as efficient as Regranex Phase I/II study on 200 diabetic patients in India Incidence of complete wound closure after 20 weeks Once a day 66% 31/47 79% 38/48 Once every 2 days Registered in clinical trials.gov #NCT ; 192 patients (both neuroischemic and neuropathic) Property of Adocia 49
50 BioChaperone PDGF Two products for two markets Clinical proof of concept established in Phase I/II on DFU (India) 80% Neuropathic Emerging markets WHO-GMP PDGF Western markets cgmp PDGF 60% Neuroischemic Phase III clinical trial dossier filed (India) EMA-validated shortened clinical development plan Phase III study launched September 2014 Next steps Pre-IND meeting planned 2Q 15 European Phase III 4Q 15 Property of Adocia 50
51 BioChaperone PDGF: Phase III clinical study launched in India Approval by DCGI received August 22, 2014 Phase III clinical study 252 diabetic patients presenting a diabetic foot ulcer Comparing Biochaperone PDGF-BB to placebo investigators centers Study to be managed by the CRO Makrocare Investigators meeting on September 6, in Hyderabad Goal of the study: to confirm the effectiveness of the product Obtain the data to support marketing approval in India and other emerging countries Support the results of an Phase III trail in Europe Principal criteria: Complete wound healing after a maximum of 20 weeks of treatment Secondary criteria: Wound healing in 10 weeks Recurrence rate of the wound healing after 3 months Results expected 1Q2016 Property of Adocia 51
52 Products breakthrough 1. Insulin therapy 2. Wound healing 3. Oncology September 2014 Property of Adocia 52
53 Adocia in Oncology Monoclonal Antibodies Formulation DriveIn To improve the solubility To reduce viscosity in highly concentrated solution To improve the stability in storage 2 ongoing partnerships with major pharmaceutical companies Targeted delivery for chemotherapy Biomimetic hyaluronan-based Trojan horse Phase 1 planned to start 4Q 2015 September 2014 Property of Adocia 53
54 Financial Statements September 2014 Property of Adocia 54
55 2014 Annual results: brief statement of accounts In thousands (IFRS rules) 30/06/ /06/2013 Variation Revenue 0,2 0,9 Other income 1,7 1,8 Total income 1,9 2,7-30% Operating expenses (7,4) (7,4) Profit/loss from operating activities (5,6) (4,6) -21% Net profit/loss after tax (5,5) (4,6) -20% September 2014 Property of Adocia 55
56 2014 Annual results: published key figures Cash position end of June 2014: 15,9M Burnt rate on the 1st quarter 2014: 3,5M (3,2M cash in June 2014 of the tax credit research on 2013 spending) Long term debt: 1,8M loan from BPI France (refundable only in case of commercial and/or technical success) September 2014 Property of Adocia 56
57 Shareholders as of June 30, 2014 Listed on Euronext Paris since February ,2 million shares, with a float of 37% (*) Market capitalization = 100M Shareholders equity ADR Program with BNY since May 2014 (ADOCY) Analysts: Kepler Market (Lionel Labourdette) Invest Securities (Daniel Anizon) Life Sci Advisors (Andrew I. Mc Donald) (*) incluant, le cas échéant, les actions détenues par les investisseurs historiques de la société September 2014 Property of Adocia 57
58 Adocia Next steps September 2014 Property of Adocia 58
59 Adocia Next steps Product / Technology Therapeutic area Event Expected timeline Biochaperone Combo Diabetes Phase IIa dose-response study launch 4Q-2014 Hinsbet Diabetes Phase IIa dose-response study results 4Q-2014 Biochaperone Lispro U100 Diabetes Phase IIa, pump study, post meal launch 1Q-2015 Biochaperone Lispro U300 Diabetes Phase I study launch 1Q-2015 mabs technologies Depending on partner Ongoing collaborative developments - DriveIn Oncology Phase I launch 4Q-2015 BC PDGF-BB Diabetes Phase III Europe study launch 4Q-2015 BC PDGF-BB Diabetes Phase III India Results 1Q-2016 Property of Adocia 59
60 Thank you for your kind interest Persons depicted in this document are models that are intended to enhance the presentation. They are not affected by any disease or treatments mentioned in this present document. Contact 115 avenue Lacassagne Lyon Tél SA au capital de ,60 - RCS Lyon September 2014 Property of Adocia 60
Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationSolomon S. Steiner, Lutz Heinemann, Roderike Pohl, Frank Flacke, Andreas Pfützner, Patrick V. Simms, Marcus Hompesch. EASD September 18, 2007
Pharmacokinetics and Pharmacodynamics of Insulin VIAject TM, Insulin Lispro and Regular Human Insulin When Injected Subcutaneously Immediately Before a Meal in Patients with Type 1 Diabetes. Solomon S.
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationBreakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationMANNKIND CORPORATION (NASDAQGM: MNKD)
UPDATE REPORT Pharmaceutical Industry February 15, 2013 KEITH A. MARKEY, PH.D., M.B.A. 212-514-7914 KMARKEY@GRIFFINSECURITIES.COM MANNKIND CORPORATION (NASDAQGM: MNKD) CLINICAL TRIALS ON SCHEDULE & FINANCES
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationInsulin: A Practice Update. Department of Nursing Staff Development Elizabeth Borgelt, MS, RN
Insulin: A Practice Update Department of Nursing Staff Development Elizabeth Borgelt, MS, RN Learning Outcome The learner will be able to identify the different types of insulins available, their actions,
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationInsulin Administration: What You Don t Know May Hurt Your Patient
Insulin Administration: What You Don t Know May Hurt Your Patient Jaime A. Davidson, MD, FACP, MACE Clinical Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Jaime A. Davidson,
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationSponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationDIABETES MEDICATION INSULIN
Section Three DIABETES MEDICATION INSULIN This section will tell you: About insulin. How to care and store your insulin. When to take your insulin. Different ways of taking insulin. WHAT IS INSULIN? Insulin
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:
More informationSlide 1. Virksomhedsdagen 2013 Den Danske Finansanalytikerforening. Jesper Brandgaard, CFO. June 2013
Slide 1 Virksomhedsdagen 2013 Den Danske Finansanalytikerforening Jesper Brandgaard, CFO June 2013 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationClinical Validity of Insulin Bolus Calculators
Clinical Validity of Insulin Bolus Calculators Howard A. Wolpert, MD Senior Physician, Joslin Diabetes Center Associate Professor, Harvard Medical School Director, Joslin Institute for Technology Translation
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationGuideline for Insulin Therapeutic Review in patients with Type 2 Diabetes
Diabetes Sans Frontières Guideline for Insulin Therapeutic Review in patients with Type 2 Diabetes 1. Introduction This guideline has been developed in order to support practices to undertake insulin therapeutic
More informationINSULIN PRODUCTS. Jack DeRuiter
INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationManaging the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS
Managing the Hospitalized Patient on Insulin: Care Transition Catie Prinzing MSN, APRN, CNS Diabetes and Hospitalization People with DM are hospitalized 3x more frequently than patients without diabetes
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationInsulin T Y P E 1 T Y P E 2
T Y P E 1 T Y P E 2 INSULIN There are many different insulins for many different situations and lifestyles. This section should help you and your doctor decide which insulin or insulins are best for you.
More informationOnset Peak Duration Comments
Rapid- Acting 5-15 minutes 0.5-3 hours 3-5 hours Meal should be available before administering, ideally taking within 10 minutes of eating). Good in refrigerator (36-46 F) until expiration date. Protect
More informationInsulin Pens & Improving Patient Adherence
Insulin Pens & Improving Patient Adherence Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Kip Benko, MD FACEP Asst Clinical Professor University of Pittsburgh School
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationLipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series
Lipodystrophy: Metabolic and Clinical Aspects Resource Room Slide Series Current Thinking About the Diagnosis and Treatment of the Insulin-Resistant State: How to Use Insulin Therapy Irl B. Hirsch, MD
More informationTypes of insulin and How to Use Them
Diabetes and Insulin Pumps Amy S. Pullen Pharm.D ISHP Spring Meeting April 2012 Objectives Describe the different types of insulin used in diabetes Identify the types of insulin that are compatible with
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationObjectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate
More informationOptimizing Insulin Therapy. Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors
Optimizing Insulin Therapy Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors Introduction Diabetes management, and particularly self-management, has come a long way. Unfortunately,
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationSTATE MEDICAID P&T COMMITTEE MEETING FRIDAY, November 16, 2007 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 114 MINUTES
STATE MEDICAID P&T COMMITTEE MEETING FRIDAY, November 16, 2007 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 114 Committee Members Present: Kort DeLost, R.Ph. David Harris, M.D. Koby Taylor, PharmD.
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationCriteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationValneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013
Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More information2010 Partners & Peers for Diabetes Care, Inc. www.partnersandpeers.org
Without a working knowledge of the way insulin works in your body it is very difficult to effectively manage diabetes... Kind of like driving a car without knowing how to use the gas pedal and brakes...
More informationInsulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed
More informationINSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES
INSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES Young Jun Rhie, M.D. Department of Pediatrics Korea University Ansan Hospital Introduction 1 Children and adolescents with type 1 diabetes
More informationEfficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus
Clin Pediatr Endocrinol 2002; 11(2), 87-92 Copyright 2002 by The Japanese Society for Pediatric Endocrinology Original Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Toshikazu
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationPremixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s
Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationHigh Dose Insulin Therapy: The case for CONCENTRATED Insulin
High Dose Insulin Therapy: The case for CONCENTRATED Insulin 21 st Annual Diabetes Fall Symposium Charleston, SC Wendy Lane MD September 18, 2015 Mountain Diabetes and Endocrine Center Asheville, North
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationFor Educational Use Only - Not for Detailing or Distribution
This document is intended for healthcare professionals practicing in the United States and may contain information that has not been approved by the FDA. It is supplied to you as a professional courtesy
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationTHE INS AND OUTS OF INSULIN. Mary Beth Wald, RN,BSN,CDE
THE INS AND OUTS OF INSULIN Mary Beth Wald, RN,BSN,CDE WHAT HAPPENS IN MY BODY? When we eat, the food gets changed into glucose, a type of sugar. Glucose travels in the blood to all the cells in your body
More informationLibyan International Medical University www.limu.edu.ly PBL-III. ZuhirBodalal
Libyan International Medical University www.limu.edu.ly PBL-III ZuhirBodalal Disclaimer The following is a collection of medical information from multiple sources, both online and offline. It is to be
More informationInsulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020
Brochure More information from http://www.researchandmarkets.com/reports/2075322/ Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Description: Insulin Degludec (Type 2 Diabetes) Analysis
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationDiabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C
Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationSlide 1. Diabetes care strategy. Lars Fruergaard Jørgensen EVP Corporate Development
Slide 1 Diabetes care strategy Lars Fruergaard Jørgensen EVP Corporate Development Diabetes care strategy Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
More informationIntroduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.
Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationat The Valley Hospital (TVH) for Nursing Students/Nursing Instructors 2012
at The Valley Hospital (TVH) for Nursing Students/Nursing Instructors 2012 Subject - Insulin Safety Background Insulin known to be high risk medication Can promote serious hypoglycemia if given incorrectly
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationTRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES. Presenting at Småbolagsdagen June 10, 2013
TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES Presenting at Småbolagsdagen June 10, 2013 LEGAL DISCLAIMER This presentation, which is personal to the recipient, has been prepared
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationHow To Sell A Share In Amsterdam Molecular Therapy
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext
More information